Core Viewpoint - Surgery Partners, Inc. plans to offer an additional $425 million of its 7.250% senior unsecured notes due 2032 to support general corporate purposes, including repaying outstanding borrowings [1][2] Group 1: Company Overview - Surgery Partners is a leading healthcare services company focused on high-quality, cost-effective surgical and ancillary care solutions, operating over 200 locations across 30 states [4] - The company was founded in 2004 and has become one of the largest and fastest-growing surgical services businesses in the United States [4] Group 2: Financial Offering Details - The additional notes will be guaranteed on a senior unsecured basis by each domestic wholly-owned subsidiary of the Issuer that guarantees its obligations under senior secured credit facilities [1] - The notes will be part of the same series as the previously issued 7.250% senior notes due 2032, originally issued in April 2024 [1]

H1 2025: 28% TTV Growth, 12% Revenue Growth, Liabilities Cut by $65M, Turkey Expansion SecuredLONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- RedCloud Holdings plc (Nasdaq: RCT) (“RedCloud” or the “Company”) the technology company building intelligent infrastructure for global trade today reported first half results, with RedAI platform. In H1, the company added another $1.2 billion in trading volume — up 28% year-over-year. Revenue for H1 2025 reached $17.9 million, up 12% year-over-year. For full year 2025, Re ...

Core Insights - Polyrizon Ltd. has announced promising results from its preclinical evaluation of an intranasal naloxone hydrogel formulation, highlighting its potential for improved drug delivery in emergency situations [1][4]. Group 1: Product Development - The company has demonstrated significantly enhanced mucoadhesion of its formulation on ex-vivo nasal tissue compared to a marketed product, with a p-value of less than 0.0001 [2]. - Permeation studies indicate that despite improved mucoadhesion, the hydrogel maintains rapid permeation kinetics comparable to existing naloxone products, ensuring fast action in emergencies [3][8]. - The results from stability, mucoadhesion, and permeability studies collectively position Polyrizon's naloxone hydrogel for further development stages [8]. Group 2: Market Context - The opioid crisis is escalating, with over 80,000 deaths annually in the U.S. due to opioid overdoses, necessitating improved naloxone delivery systems [5]. - The global naloxone market is projected to reach several billion dollars in the coming years, driven by public health initiatives and regulatory support for innovative products [5]. - Intranasal formulations are preferred for their ease of use and rapid action, making technologies like Polyrizon's hydrogel critical for enhancing treatment reliability during overdose events [5]. Group 3: Company Overview - Polyrizon specializes in developing innovative medical device hydrogels for intranasal delivery, aiming to create a barrier against viruses and allergens while enhancing drug retention [6]. - The company's proprietary technologies include Capture and Contain™ and Trap and Target™, focusing on improving bioadhesion and prolonged retention for drug delivery [6].

Core Insights - Biomerica, Inc. has received authorization from the Egyptian Drug Authority for its complete portfolio of rapid diagnostic tests, enhancing access to early detection tools for cancer and chronic diseases in Egypt [1][2][10] Product Portfolio - The authorized screening tests include those for colorectal disease, breast self-examination, prostate disease, kidney disease, and H. pylori infection, all designed for point-of-care use [1][3][7] - Tests provide quick results within minutes and do not require laboratory sample processing, making them suitable for diverse clinical and community settings [3][14] Market Need - Colorectal cancer is the 7th most common cancer in Egypt, with an incidence of approximately 5 to 10 cases per 100,000 persons per year, and a concerning trend of late-stage diagnoses [4] - Breast cancer is the most common cancer among women in Egypt, with an age-standardized incidence rate of about 55.4 per 100,000 persons per year, and poorer mortality outcomes due to late-stage diagnosis [5] - Prostate cancer ranks as the fourth most common cancer in Egypt, with increasing incidence rates [6] Health Statistics - Approximately 13% of adults in Egypt are living with chronic kidney disease, which has been among the top five causes of death from 2009 to 2019 [8] - H. pylori infection prevalence in Egypt ranges from 50% to 70%, affecting a significant portion of the population [8] Strategic Impact - The authorization supports national public health efforts to improve early disease detection, enhance health outcomes, and reduce long-term healthcare costs [9][10] - Biomerica's expansion in the Middle East and North Africa (MENA) region is reinforced by this authorization, aligning with global preventive care trends [11]

Core Insights - XBP Global Holdings, Inc. has entered into a five-year agreement with BG-Phoenics GmbH, valued at up to 21.5 million Euro, to provide workflow automation services in Germany's statutory accident insurance sector [1][2][4] Group 1: Agreement Details - The contract involves XBP Global transitioning the client's mail processing from paper-based workflows to AI-driven digital document management [2][4] - XBP Global will utilize its Intelligent Document Processing (IDP) Software platform to process and digitize up to 148 million pages during the contract period [3][4] Group 2: Strategic Positioning - This agreement enhances XBP Global's presence in the German public sector and reinforces its reputation as a strategic partner for technology-enabled document management services [2][4] - The engagement follows a competitive tender process and aligns with XBP Global's strategy to strengthen its foothold in regulated industries and key European markets [4] Group 3: Company Overview - XBP Global operates in 20 countries with approximately 11,000 professionals and partners with over 2,500 clients, including many Fortune 100 companies [6][7] - The company focuses on intelligent workflows and hyper-automation, leveraging its proprietary platforms and AI-driven automation to support digital transformations [7]

Core Insights - Cadrenal Therapeutics has acquired VLX-1005 and related 12-LOX assets from Veralox Therapeutics, enhancing its pipeline with a late-stage drug candidate aimed at the $40 billion global anticoagulation market [1][4] Company Overview - Cadrenal Therapeutics is focused on developing innovative therapeutics to address gaps in anticoagulation management for high-risk patient populations, with three clinical-stage assets including VLX-1005, tecarfarin, and frunexian [6] Product Details - VLX-1005 is a selective small-molecule inhibitor of 12-LOX, targeting immune platelet-mediated inflammation and addressing heparin-induced thrombocytopenia (HIT), which affects up to 5% of patients exposed to heparin [2][8] - The drug has received Orphan Drug Designation and Fast Track designation from the FDA, indicating its potential significance in treating rare conditions [4][8] Clinical Development - Phase 1 studies of VLX-1005 showed it was well tolerated with no serious adverse events, while a Phase 2 study indicated promising reductions in thromboembolic events among patients with suspected HIT [3][4] - The market for HIT treatment is estimated to reach $1 billion in the US and EU, highlighting the commercial potential of VLX-1005 [5] Acquisition Terms - The acquisition agreement includes upfront and milestone payments to Veralox contingent on future clinical and regulatory achievements, as well as royalties on global sales of VLX-1005 [5]

Dubai and Dhaka, December 11, 2025 - VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON”), today announces that Banglalink, its digital operator in Bangladesh, has received the permission of Bangladesh Bank to operate as a payment service provider - a milestone in the operator’s ambition to expand further into digital financial services. As a payment services provider, Banglalink will be able to offer regulated money transfer and payment services for customers, expanding access to formal financial ...

Company Overview - Par Pacific Holdings, Inc. is an energy company based in Houston, Texas, providing both renewable and conventional fuels to the western United States [2] - The company operates a combined refining capacity of 219,000 barrels per day across four locations in Hawaii, the Pacific Northwest, and the Rockies [2] - Par Pacific has an extensive energy infrastructure network, including 13 million barrels of storage and various transportation assets [2] - The company operates the Hele retail brand in Hawaii and the "nomnom" convenience store chain in the Pacific Northwest [2] - Par Pacific holds a 46% stake in Laramie Energy, LLC, a natural gas production company focused on Western Colorado [2] Financial Update - Par Pacific announced a repricing of its existing term loan credit agreement due 2030, which is expected to close around December 17, 2025 [1] - The repricing amendment will reduce the Applicable Margin under the Term Loan Facility by 50 basis points, resulting in interest rates of 2.25% for Base Rate loans and 3.25% for SOFR loans [1]

Core Viewpoint - Stryker has announced a quarterly dividend increase to $0.88 per share, reflecting a 4.8% rise compared to the previous year and quarter [1][2]. Company Overview - Stryker is a global leader in medical technologies, focusing on improving healthcare through innovative products and services in MedSurg, Neurotechnology, and Orthopaedics, impacting over 150 million patients annually [3].

Core Insights - MAIA Biotechnology, Inc. is demonstrating strong insider confidence through recent share purchases by CEO Dr. Vlad Vitoc and board members, acquiring approximately 182,445 shares between November 21 and 28, 2025, signaling belief in the long-term value of the ateganosine platform [1][2][3] Group 1: Insider Activity - The recent insider buying reflects a unified stance from MAIA's leadership, showcasing confidence in the company's strategy and the clinical evidence supporting ateganosine as a potential therapeutic pathway for advanced non-small cell lung cancer (NSCLC) [2][3] - Directors and Officers currently hold 4,480,120 shares, representing 12.95% of the company, indicating significant insider ownership and commitment [3] Group 2: Clinical Development - Ateganosine, MAIA's lead program, is in mid- to late-stage clinical development and has shown encouraging results, enhancing both internal and external confidence in its potential as a first-in-class cancer therapy targeting telomerase-positive cancer cells [2][4] - The company's approach is positioned as a meaningful new therapeutic pathway for patients with advanced NSCLC, highlighting the innovative nature of its drug development strategy [2][4]